终末期糖尿病肾病患者腹膜透析治疗的临床分析

目的：探讨终末期糖尿病肾病患者腹膜透析治疗的临床特点,采取有效措施以减少并发症,提高患者生存率.方法：回顾分析本院42例糖尿病肾病腹膜透析患者（糖尿病肾病组,DN组）的临床资料、并发症及病死率,并与作腹膜透析治疗的非糖尿病肾病患者63例（非DN组）相比较.结果：DN组与非DN组相比,白蛋白明显偏低（30.70±4.92）g/L比（37.62±4.34）g/L],而血糖值明显偏高（10.21±2.3）mmol/L比（5.8±1.22）mmol/L],差异均有统计学意义（均为P〈0.01）;DN组3年存活率较非DN组患者低,差异有统计学意义（P〈0.01）;DN组患者的并发症比非DN组多,主要为心血管并发症、感染、脑血管意外、营养不良.结论：糖尿病肾病尿毒症患者应积极控制血糖,纠正低蛋白血症,减少心脑血管并发症的发生.

Peritoneal dialysis in patients with end-stage diabetic nephropathy :a clinical analysis

Objective： To explore the clinical picture of peritoneal dialysis （PD） in patients with end-stage diabetic nephropathy, so as to reduce complications and increase the patient survival rate. Methods： Forty-two patients with diabetic nephropathy （DN group） who received PD in our hospital were retrospectively analyzed for clinical data,complications and death rate, compared with those on PD but without diabetic nephropathy （Non-DN group）. Results：Compared with the Non-DN group, DN group had significantly lower level of albumin （30.70 ± 4. 92）g/L vs （37.62 ± 4.34） g/L ] but higher level of blood glucose （ 10.21 ± 2.3 ） mmol/L vs （5.8 ± 1.22 ） mmol/L] ,which reached the level of statistical difference （P 〈0.01 ）. The three-year-survival rate among patients of DN group were lower than those among the Non-DN group patients（ P 〈0.01 ）. More comphcations were found in DN group than in Non-DN group, which mainly included cardiovascular complications, infection, cerebrovascular events and malnutrition. Conclusion：Patients with diabetic nephropathy or uremia should be on active control of blood glucose and aggressive remedy for hypoproteinemia, so as to reduce cardiovascular complications.